The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(1,4-diazabicyclo[3.2.2]nonan-4-yl)(3-(4-(trifluoromethyl)phenyl)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)methanone ID: ALA5273314
Max Phase: Preclinical
Molecular Formula: C21H23F3N4O2
Molecular Weight: 420.44
Associated Items:
Names and Identifiers Canonical SMILES: O=C(N1CCN2CCC1CC2)n1nc(-c2ccc(C(F)(F)F)cc2)c2c1COCC2
Standard InChI: InChI=1S/C21H23F3N4O2/c22-21(23,24)15-3-1-14(2-4-15)19-17-7-12-30-13-18(17)28(25-19)20(29)27-11-10-26-8-5-16(27)6-9-26/h1-4,16H,5-13H2
Standard InChI Key: SHQCJGRSHYCIQP-UHFFFAOYSA-N
Molfile:
RDKit 2D
30 34 0 0 0 0 0 0 0 0999 V2000
0.6393 -2.8850 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4258 -2.0881 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.9754 -1.4836 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7006 -0.6868 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0961 -0.5220 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.6457 -1.1264 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3984 -1.9232 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3434 0.2473 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.1402 0.5221 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.8546 0.1099 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5690 0.5221 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5690 1.3464 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-1.8546 1.7585 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.1402 1.3464 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3434 1.5936 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.1510 0.9342 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.0961 2.3630 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.6731 2.9675 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
0.7006 2.5553 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.9204 3.3521 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1952 2.6652 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8546 2.3355 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5690 2.5279 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.0469 1.8959 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2226 1.8959 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4041 3.3247 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6623 3.6818 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4362 -3.0985 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
0.0560 -3.4683 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
0.8529 -3.6818 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
2 3 2 0
3 4 1 0
4 5 2 0
5 6 1 0
7 2 1 0
6 7 2 0
8 5 1 0
9 8 1 0
10 9 1 0
11 10 1 0
12 11 1 0
12 13 1 0
9 14 2 0
14 13 1 0
14 15 1 0
8 16 2 0
15 16 1 0
15 17 1 0
17 18 2 0
17 19 1 0
20 19 1 0
20 21 1 0
21 22 1 0
22 23 1 0
23 24 1 0
19 25 1 0
25 24 1 0
23 26 1 0
20 27 1 0
27 26 1 0
1 28 1 0
1 29 1 0
1 30 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 420.44Molecular Weight (Monoisotopic): 420.1773AlogP: 3.39#Rotatable Bonds: 1Polar Surface Area: 50.60Molecular Species: NEUTRALHBA: 5HBD: ┄#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): ┄#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 7.78CX LogP: 2.31CX LogD: 1.78Aromatic Rings: 2Heavy Atoms: 30QED Weighted: 0.71Np Likeness Score: -0.82
References 1. Roecker AJ, Schirripa KM, Loughran HM, Tong L, Liang T, Fillgrove KL, Kuo Y, Bleasby K, Collier H, Altman MD, Ford MC, Drolet RE, Cosden M, Jinn S, Hatcher NG, Yao L, Kandebo M, Vardigan JD, Flick RB, Liu X, Minnick C, Price LA, Watt ML, Lemaire W, Burlein C, Adam GC, Austin LA, Marcus JN, Smith SM, Fraley ME.. (2023) Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's Disease., 14 (2.0): [PMID:36793422 ] [10.1021/acsmedchemlett.2c00441 ]